What's new

Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Date of authorisation: 18/02/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Date of authorisation: 18/02/2021, Revision: 7, Status: Authorised

Mar 31, 2025 - 13:04
 0
Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Date of authorisation: 18/02/2021, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Date of authorisation: 18/02/2021, Revision: 7, Status: Authorised
Read More

Tags:

Previous Article

Daimler Buses acquires a stake in software company SINOS

Next Article

Hedge funds fight over one of Europe’s largest lingerie brands

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0478/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025  0

Summary of opinion: Calquence, 27/02/2025 Positive

Summary of opinion: Calquence, 27/02/2025 Positive

Feb 28, 2025  0

Human medicines European public assessment report (EPAR): Vevizye, ciclosporin, Date of authorisation: 19/09/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025  0